San Carlos, United States
ELEGEN, established in 2017 and headquartered in the United States, is poised at the vanguard of the synthetic biology revolution. With its slogan, “Unlock the promise of synthetic biology by accelerating the Design-Build-Test-Learn cycle,” the company is committed to transformative innovation in DNA writing technology. This innovative approach aims to deliver DNA writing with unmatched speed, cost-efficiency, and quality, which is crucial for reprogramming biological processes to address major global challenges.
Founded by Dr. Matthew Hill, an alumnus of Stanford with a history of steering tech innovations to market success, ELEGEN boasts a leadership team enriched with seasoned experts such as Dr. Marc Unger, inventor of the Nanoflex™ valve. The company's forward trajectory is strongly backed by renowned investors like Andreessen Horowitz, 8VC, and KdT, ensuring its robust financial and strategic positioning within the life sciences sector.
